Biotech Growth Trust PLCLSE: BIOG

The Biotech Growth Trust PLC - Transaction in Own Shares

· Issued by Biotech Growth Trust PLC via PR Newswire

Summary by 6ix AI

The Biotech Growth Trust PLC bought 115,000 of its ordinary shares of 25p each in the market on October 23, 2026, at a price of 1355.20 pence per share. The shares are to be cancelled.

Key details

  • The purchase was made under authority granted at the Annual General Meeting on July 16, 2026, which allows the Company to buy back up to an aggregate maximum of 2,864,231 of its own shares.
  • Following the purchase, the total number of voting rights in the Company is 18,424,477. The Company does not currently hold any ordinary shares in treasury (shares bought back and held rather than cancelled).
  • Shareholders may use the 18,424,477 figure to work out whether they must report their holding, or a change to it, under the Disclosure Guidance and Transparency Rules of the FCA, the UK Financial Conduct Authority.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/the-biotech-growth-trust-plc-transaction-in-own-shares-1

                          For immediate release

23 October 2026

THE BIOTECH GROWTH TRUST PLC

(the "Company")

MARKET PURCHASE OF COMPANY'S OWN SHARES

Notification is given, pursuant to the authority granted at the Annual General
Meeting of the Company held on 16 July 2026 to make market purchases of the
Company's own shares up to an aggregate maximum of 2,864,231 that a market total
of 115,000 Ordinary shares of 25p each in the capital of the Company were
purchased today for cancellation by the Company at a price of 1355.20 pence per
share.

Following this transaction, the Company hereby notifies the market that the
total number of Ordinary shares that the Company has in issue, less the total
number of Ordinary shares bought back for cancellation by the Company following
such purchase, and therefore, the total number of voting rights in the Company
18,424,477. The Company does not currently hold any Ordinary shares in treasury.

The figure of 18,424,477 may be used by shareholders as the denominator for the
calculation by which they may determine if they are required to notify their
interest in, or change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

For and on behalf of

Frostrow Capital LLP

Company Secretary

For further information, please contact:

Katherine Manson

Frostrow Capital LLP

Tel: 020 3709 8734


This information was brought to you by Cision http://news.cision.com

Biotech Growth Trust PLC on 6ix

Earlier from Biotech Growth Trust

Later from Biotech Growth Trust

All Biotech Growth Trust news releases